TLPH Stock Overview
A specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Talphera, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.55 |
| 52 Week High | US$1.27 |
| 52 Week Low | US$0.50 |
| Beta | 0.20 |
| 1 Month Change | -12.48% |
| 3 Month Change | -16.10% |
| 1 Year Change | -52.88% |
| 3 Year Change | -91.67% |
| 5 Year Change | -96.69% |
| Change since IPO | -99.39% |
Recent News & Updates
Recent updates
AcelRx: The Catalogue Of Catalysts - Including A Big One That Will Do Investors Well
Aug 18AcelRx Pharmaceuticals: Finally, Plan B
Jun 06AcelRx Pharmaceuticals: Making Sense Of The Q4 Numbers
Mar 16AcelRx Pharmaceuticals: The Fog Is Getting Thicker
Jan 14AcelRx: Battered And Bruised But Ready For Recovery In 2022
Jan 05AcelRx Pharmaceuticals: Is Wayne Gretzky Right Or The Puck?
Oct 02AcelRx Pharmaceuticals: How The Licensing Agreements Could Become A Shot In The Arm
Jul 27FDA agrees with AcelRx to update promotional materials for Dsuvia
Jun 17Shareholders May Find It Hard To Justify Increasing AcelRx Pharmaceuticals, Inc.'s (NASDAQ:ACRX) CEO Compensation For Now
Jun 11
AcelRx Pharmaceuticals: A Bullish View In 3 Song Titles
May 31Shareholder Returns
| TLPH | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 1.2% | -5.4% | -4.4% |
| 1Y | -52.9% | -0.5% | 7.5% |
Return vs Industry: TLPH underperformed the US Pharmaceuticals industry which returned -0.1% over the past year.
Return vs Market: TLPH underperformed the US Market which returned 6.9% over the past year.
Price Volatility
| TLPH volatility | |
|---|---|
| TLPH Average Weekly Movement | 13.3% |
| Pharmaceuticals Industry Average Movement | 10.2% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: TLPH's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: TLPH's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 15 | Vince Angotti | talphera.com |
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.
Talphera, Inc. Fundamentals Summary
| TLPH fundamental statistics | |
|---|---|
| Market cap | US$9.37m |
| Earnings (TTM) | -US$15.64m |
| Revenue (TTM) | US$281.00k |
33.4x
P/S Ratio-0.6x
P/E RatioIs TLPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TLPH income statement (TTM) | |
|---|---|
| Revenue | US$281.00k |
| Cost of Revenue | US$7.16m |
| Gross Profit | -US$6.88m |
| Other Expenses | US$8.76m |
| Earnings | -US$15.64m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.92 |
| Gross Margin | -2,449.47% |
| Net Profit Margin | -5,565.48% |
| Debt/Equity Ratio | 67.7% |
How did TLPH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/12 21:29 |
| End of Day Share Price | 2025/03/12 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Talphera, Inc. is covered by 19 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| David Buck | B. Riley Securities, Inc. |
| Andrew D'Silva | B. Riley Securities, Inc. |